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Abstract
Background: Greying with age in horses is an autosomal dominant trait, associated with loss of hair pigmentation,
melanoma and vitiligo-like depigmentation. We recently identified a 4.6 kb duplication in STX17 to be associated
with the phenotype. The aims of this study were to investigate if the duplication in Grey horses shows copy
number variation and to exclude that any other polymorphism is uniquely associated with the Grey mutation.
Results: We found little evidence for copy number expansion of the duplicated sequence in blood DNA from Grey
horses. In contrast, clear evidence for copy number expansions was indicated in five out of eight tested melanoma
tissues or melanoma cell lines. A tendency of a higher copy number in aggressive tumours was also found.
Massively parallel resequencing of the ~350 kb Grey haplotype did not reveal any additional mutations perfectly
associated with the phenotype, confirming the duplication as the true causative mutation. We identified three SNP
alleles that were present in a subset of Grey haplotypes within the 350 kb region that shows complete linkage
disequilibrium with the causative mutation. Thus, these three nucleotide substitutions must have occurred
subsequent to the duplication, consistent with our interpretation that the Grey mutation arose more than
2,000 years before present.
Conclusions: These results suggest that the mutation acts as a melanoma-driving regulatory element. The
elucidation of the mechanistic features of the duplication will be of considerable interest for the characterization of
these horse melanomas as well as for the field of human melanoma research.
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Background
Greying with age in horses is an autosomal dominant
trait, associated with a gradual loss of hair pigmentation,
a high incidence of melanoma and vitiligo-like depig-
mentation. The phenotype can be traced back through
thousands of years in European and Asian culture and
throughout history the white horse has been commonly
used to manifest purity, power and status. Consequently,
humans have favoured the phenotype in breeding over
hundreds of generations. Still today, white-coated horses
are preferred in many breeds all over the world,
particularly notably in the Lipizzaner breed used in the
world famous Spanish Riding School in Vienna.
Grey horses are born coloured and gradually lose their
hair pigmentation (Figure 1A). Most individuals in
breeds where the Grey allele is common, like Arabian,
Andalusian and Lipizzaner horses, become white by the
age of 6–8 years [1,2], and sometimes even earlier. The
pigmentation loss only affects the hair, while the skin
stays dark throughout life, indicating different cellular
fates for the melanocytes in the hair follicles and in the
skin. Melanomas are frequently occurring among many
Grey horses, usually in the later stages of life. It is gener-
ally claimed that 70-80% of Grey horses older than
15 years have melanomas [3,4]. The primary tumours
arise in the dermis of the glabrous skin, often around
the eyes, genital regions or the anus, and are usually
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benign. Internal tumours do occur but are fairly rare,
and it has not been confirmed whether these tumours
are true metastases or locally occurring from melano-
cytes residing in respective tissues. Grey horses with
melanomas also develop vitiligo-like skin depigmen-
tation, commonly seen on the muzzle and under the tail
[1], and many Grey horses have pigmented speckles in
their white fur, a phenotype known as flea-bitten Grey.
In 2008, we identified the mutation causing Greying
with age in horses, constituting a 4.6 kb intronic dupli-
cation in the STX17 gene [2]. The mutation resides on a
352 kb haplotype showing complete linkage disequilib-
rium (LD) with the Grey phenotype across eight breeds.
This interval was unexpectedly large since it was
deduced from material including both Arabian and Ice-
landic horses, two divergent breeds that have been sepa-
rated for a minimum of 1,000 years. As also indicated in
a previous study [5], this suggests a low rate of recom-
bination in the Grey interval. Additionally, one non-
Grey haplotype identical to the Grey haplotype for all
tested SNPs in the interval was suggested to represent
the “ancestral” haplotype, or at least a haplotype closely
related to Grey [2].
While the loss of hair pigmentation is fully dominant,
the speed of greying, amount of speckling, incidence of
melanomas and presence of vitiligo-like depigmentation
show considerable variation among Grey horses. Horses
homozygous for the mutation show a more rapid greying
process and tend to become whiter than heterozygous
Grey horses [2]. Homozygous individuals also show a
significantly higher incidence of melanoma and vitiligo,
while they almost lack the pigmented speckles present in
heterozygous individuals [2]. However, there is still con-
siderable phenotypic variation within the G/g and G/G
genotypes both within and across breeds with respect to
the manifestation of these traits. For example, some
individuals in the Connemara breed carrying the Grey
mutation show an extraordinarily slow rate of greying
(Figure 1B). These horses show relatively few signs of
greying as late as by 15 years of age, and many of them
never turn completely grey. The slow rate of greying
appears to be inherited within families, although the mo-
lecular reason remains unknown. Possible causes could
be an alternative allele of Grey in these horses, or genetic
variation elsewhere in the genome affecting the pene-
trance of Grey. Quantitative genetic analysis of the speed
of greying in the Lipizzaner population (unpublished)
indicates that a large genetic component, almost 60 per-
cent of the phenotypic variation as regards how quickly
a Grey horse become white (i.e. the speed of greying), is
still unexplained.
A copy number variant (CNV) is usually defined as a
region larger than 1 kb where copy number differences
have been observed between two or more genomes [6].
Duplicated loci often show variation in copy number,
which in turn may have important effects on the pheno-
type. This can be exemplified by the Pea-comb pheno-
type in chicken, where a massive and variable
amplification of a duplicated sequence in intron 1 of
SOX5 results in a dramatically reduced size of the comb
and wattles [7], and the Dominant white phenotype in
pigs, where a 450 kb duplication, or in some individuals
triplication, in KIT causes white coat colour [8-10]. In
humans, CNVs that often include large regions spanning
several genes, are an important aspect of genetic vari-
ation, and have been associated with various diseases
[11,12]. The role of CNVs in cancer is an emerging
field [13]. Acquired, or somatic, copy number altera-
tions (CNAs) in tumour DNA have for instance been
identified in lung adenocarcinoma [14] and pediatric
acute lymphoblastic leukaemias [15]. Copy number
variants in melanocytic tumours have also been investi-
gated, showing that melanomas and benign melanocy-
tic nevi have different patterns of chromosomal
aberrations [16].
In the present study, we have investigated whether the
duplication in STX17 shows copy number variation
among Grey horses. The results showed a difference in
copy number of the duplication between blood and
tumour DNA, with the highest copy number occurring
Figure 1 The Grey horse phenotype. (A) Grey horse with a dark foal. Photo: Meike Pachner. (B) A late greying Connemara horse, showing only
very few signs of hair greying by the age of 14 years. Photo: Jenny Hagenblad.
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in tumours classified as aggressive or derived from
horses that were euthanized due to internal tumours.
We also used sequence capture and next-generation se-
quencing to resequence the entire 352 kb Grey haplo-
type in order to exclude the possibility that other
polymorphisms show as complete association to the
phenotype as the STX17 duplication and may potentially
contribute to the phenotype. We did not find any other
mutation showing such a complete association with the
Grey phenotype and thus the duplication in STX17 can
be said to be well established as being causative for
Greying with age.
A
B
C
Figure 2 (See legend on next page.)
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Results
Amplification of the duplication frequently occurs in
tumour DNA but not in germline
Ninety-four homo- and heterozygous Grey Lipizzaner
horses were tested for the copy number of the dupli-
cated sequence in constitutional DNA using a TaqMan
copy number assay. The results showed the expected
clustering of copy number according to zygosity for
Grey, and the clear separation of the Grey genotype
groups did not indicate a frequent variation in copy
number (Figure 2A). Analysis of tumour DNA from
three horses, of which two were euthanized due to nu-
merous internal melanomas (Table 1), and in two equine
melanoma cell lines originating from aggressive tumours
(Ho-Mel-A1, M14), revealed a striking expansion of the
duplicated sequence, estimated to 5–8 copies (marked
by an asterisk in Figure 2B).
Three different probes were initially used in the Taq-
Man assay (Figure 2B); BP n located at the 5' border of
the duplicated sequence, which is expected to be single
copy if the expansion only involves the 4.6 kb tandem
duplication; IN located within the duplicated sequence;
and OUT located 1.5 kb downstream of the duplication,
also expected to be a single copy if the expansion only
involves the tandem duplication. All samples, except
one, showed a normal copy number of 2.0 for both the
probe at the 5’border of the duplication (BP n) and the
probe outside (OUT) the duplication (Figure 2B and
Additional file 1), implying that the higher copy number
in tumours represents a specific amplification of the
duplicated sequence rather than amplifications of a lar-
ger genomic region as often observed in tumour DNA.
Only one tumour DNA sample, from individual ID3,
showed a slightly higher copy number for one of the
flanking probes (Figure 2B). When the region was
sequenced by Sanger sequencing, no polymorphism
could be detected in the probe site that would explain a
lower binding affinity of the TaqMan probe, and hereby
(See figure on previous page.)
Figure 2 Copy number variation of the STX17 duplication. (A) Copy number assay for the STX17 duplication in constitutional DNA from 94
Grey Lipizzaner horses and one calibrator sample with a known copy number of 2. Mean copy number G/g = 2.58, G/G = 3.84, SEM (standard
error of the mean) G/g = 0.05, G/G = 0.05. (B) Copy number assay for the STX17 duplication in constitutional DNA and/or melanoma DNA (c =
constitutional DNA, mel = melanoma DNA) using three different probes; IN = inside the duplicated sequence, OUT = outside the duplicated
sequence and BP n = the border between the 5’flanking sequence and the 5’end of the duplicated sequence. The sample denoted ‘Calibr’ is a
g/g individual with a known copy number of 2, used as a calibrator in the analysis. Constitutional DNA from one G/g and one G/G horse was
tested in the assay and the results are shown as a reference for the copy number expected from each genotype. Brackets surround the equine
melanoma cell lines or the paired constitutional and melanoma DNA samples. Error bars represent the copy number range from the
CopyCaller™ Software analysis of quadruplicates in each assay. Samples showing a copy number expansion are marked with an asterisk.
(C) Copy number assay for the STX17 duplication breakpoint in constitutional DNA and/or melanoma DNA (c = constitutional DNA,
mel = melanoma DNA) using the probe BP d = over the duplication breakpoint. The G/G reference sample was used as a calibrator in the
analysis. Error bars represent the copy number range from the CopyCaller™ Software analysis of quadruplicates in each assay.
Table 1 Samples used in the TaqMan Copy Number Assay for the Grey locus
ID Grey Type2 Breed Comments
Calibrator g/g C_DNA Arabian Calibrator in analysis
Ref G/g C_DNA Thoroughbred Genotype reference
Ref G/G C_DNA Lipizzaner Genotype reference
SP1 G/g1 C_DNA Connemara Late greying phenotype
SP2 G/g1 C_DNA Connemara Late greying phenotype
SP3 G/g1 C_DNA Connemara Late greying phenotype
Ho-Mel-L1 G/g Equine melanoma cell line Lipizzaner Normal growth
Ho-Mel-A1 G/g Equine melanoma cell line Arabian Fast growth
M1 G/g Equine melanoma cell line Irish warmblood Normal growth
M14 G/G Equine melanoma cell line Andalusian Fast growth
ID1 G/g tumour DNA Thoroughbred Euthanized due to melanoma tumours
ID2 G/G C_DNA + tumour DNA Shagya Arabian Euthanized due to melanoma tumours
ID3 G/g C_DNA+ tumour DNA Swedish warmblood Euthanized due to melanoma tumours
ID4 G/g C_DNA + tumour DNA Connemara Cremello coloured3, euthanized due to laminitis, very small melanomas
1 Not genotyped with Grey long-range PCR assay due to fragmented DNA; inferred genotype from copy number assay.
2 C_DNA = constitutional genomic DNA from blood or hair samples.
3 Cremello horses are homozygous for a missense mutation D153N in SLC45A2 (MATP) and show a severe dilution of pigmentation in hair, skin and eye [25].
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a false score in the analysis. To further corroborate the
interpretation that the higher copy number in some
tumours is caused by a local amplification of the entire
tandem duplication we added a fourth TaqMan probe
(BP d; Figure 2C) located exactly at the unique break-
point between the two tandem copies on Grey chromo-
somes, this probe is expected to be present in n-1 copies
if there is a local amplification of the entire duplicated
sequence. The results for four out of the five tumour
samples were fully consistent with a local amplification
of the duplicated sequence (Figure 2C).
One non-aggressive tumour and constitutional DNA
from the same individual (ID4), showed an equal copy
number in both tumour and constitutional DNA, close
to the expected three copies for a heterozygous Grey
horse. DNA from two non-aggressive horse melanoma
cell lines (Ho-Mel-L1, M1) also yielded a copy number
of 3.0, in accordance with their Grey genotype deter-
mined by a diagnostic long-range PCR test.
The late greying Connemara horses showed the
expected heterozygote copy number of three for the
duplicated sequence, one for the duplication breakpoint
and two copies of the flanking sequences (Additional file 2),
verifying that these horses do indeed carry the Grey
duplication.
The Grey duplication is confirmed by coverage analysis of
targeted resequencing
Two individuals were chosen for resequencing of the
352 kb region surrounding the Grey locus, one Lipizza-
ner horse homozygous for Grey and one non-Grey
chestnut Arabian horse carrying the closely related
haplotype, a haplotype identical to Grey for all tested
polymorphisms except for the duplication [2]. This ex-
perimental design was chosen to minimize the number
of sequence polymorphisms identified as uniquely asso-
ciated with Grey in this limited sample of resequenced
horses but being non-causative. In addition, five other
non-Grey horses were included in the experiment.
The read depth varied considerably between the sam-
ples, with good to exceptionally good coverage obtained
for the homozygous Grey Lipizzaner, the non-Grey
Arabian and three other non-Grey horses, with two
non-Grey samples showing adequate coverage for SNP
calling, but not as impressive as for the rest (Table 2).
This heterogeneity can in all likelihood be attributed to
differences in the efficiency of enrichment between the
samples (data not shown). The duplication associated
with the Grey phenotype was readily observed when
read depth was examined for the Grey individual across
the whole resequenced region (Figure 3A).
SNP calling was performed on alignments to the
repeat-masked reference sequence (Table 2). We identi-
fied more than 750 SNPs in the region, in average 2
SNPs/kb, but the homozygous Grey horse carried a
unique allele not present in the non-Grey horses at only
15 loci. The Grey homozygous Lipizzaner horse was
scored as heterozygous at six of these loci, but Sanger-
based resequencing revealed that all these putative het-
erozygous positions, except one at position 6,587,140 bp,
were false positives. For 7 of the 10 remaining loci, the
Grey homozygous Lipizzaner horse was either heterozy-
gous or homozygous for the non-reference allele
whereas the six non-Grey horses were homozygous for
the non-reference allele at the remaining three SNPs
(Figure 3B). The thoroughbred mare, named Twilight,
from which the genome sequence was derived, is hetero-
zygous at the Grey locus [17]. Thus, we postulated that
the seven SNPs unique to the Grey Lipizzaner horse are
in an area derived from her non-Grey allele, whereas the
three non-Grey SNPs are in an area where the genome
sequence is derived from Twilight's Grey allele.
The duplication is the only polymorphism uniquely
associated with the Grey phenotype
The 10 SNPs uniquely associated with the Grey homozy-
gote in the resequencing analysis were further investi-
gated by Sanger sequencing of three additional horses;
Twilight, the heterozygous horse used to generate the
reference sequence, a second homozygous Grey Lipizza-
ner horse and a second g/g non-Grey animal carrying a
haplotype closely related to Grey. Two loci were
excluded because the allele was also detected on a non-
Grey haplotype and we failed to resequence one of these
Table 2 Statistics for alignment of sequence reads from the 352 kb region associated with the Grey allele
Breed
Lipizzaner Arabian Noriker Icelandic Knabstrupper Appaloosa Quarter Horse
Grey genotype G/G g/g g/g g/g g/g g/g g/g
Reads Av. cover 96 52 7 102 29 10 101
SNPs Homozygous 101 103 133 422 67 18 100
Heterozygous 6 13 6 3 247 47 145
Total 107 116 139 425 314 65 245
Data from eight horses representing seven different breeds were compared with the horse genome reference sequence (Sep. 2007 Broad/EquCab2 assembly).
SNP calling was performed based on alignments with the horse reference sequence.
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SNPs (Figure 3B). This left seven loci that were selected
for further analysis.
TaqMan SNP assays were successfully designed for five
of the remaining SNPs (SNP1, SNP2, SNP3, SNP4 and
SNP6; Figure 3B and Table 3) and these were genotyped
in 357 Grey and non-Grey horses from 8 different
breeds to reveal their association pattern to the Grey
phenotype. The genotyping assays for SNP5 and SNP7
Figure 3 Targeted resequencing of the Grey haplotype. (A) Depth of coverage given by sequences obtained from targeted resequencing
experiment aligned to horse genome reference sequence (EquCab2) confirms the Grey duplication in STX17; the region presented is the one that
is essentially identical-by-descent among all Grey horses tested so far. Upper graph: Grey horse (ID L147, G/G). Middle: Chromosomal coordinates,
with genes and the Grey duplication indicated. SNPs investigated in detail are marked by numbers 1–7. Lower graph: Non-Grey horse (ID 800,
g/g). Data derived from 75 bp non-sliding windows. (B) SNPs detected by targeted resequencing and found to be unique to the homozygous
Grey Lipizzaner horse L147, or homozygous for a non-reference allele in all six non-Greys, including individual 800 having a haplotype closely
related to the Grey haplotype. The Grey genotype is based on the genotype of the Lipizzaner horse L147. The non-Grey genotype is based on
the genotype of all sequenced non-Grey horses. SNPs were selected for further analysis based on Sanger sequencing of Twilight (the Grey
heterozygote used to generate the horse reference sequence), one additional Grey homozygote and one horse homozygous non-Grey carrying
a haplotype closely related to Grey. Abbreviations: NT: Not tested for technical reasons, SEL: Selected for further analysis, SS: Sanger sequencing,
NE: Not exclusive to Grey.
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Table 3 TaqMan genotyping of SNPs in the Grey region
Polymorphism1
ID Breed Grey SNP0 SNP1 Dup SNP2 SNP3 SNP4 SNP5 SNP6 SNP7
231 Arabian g/g A - C G C A
446 Thoroughbred g/g A - C G C A
1107 New Forest Pony g/g A - C G C A
1268 Icelandic g/g A - C G C A
2857 Connemara g/g A - C G C A
5772 Shetland g/g A - C G C A
S062 Lipizzaner g/g A - C G C A
6605 Shetland g/g A - C G T/C A/G G/A A
1270 Icelandic g/g A - C - T/C A/G G/A A
435 Arabian g/g A - C/T* G C A
456 Arabian: Anc g/g A - C/T G C A
800 Arabian: Anc g/g A - C/T G C A A A
6972 Welsh g/g A - C/T G C A
D011 Lipizzaner g/g A - C/T* G C A
S046 Lipizzaner g/g A - C/T G C A
6942 New Forest Pony G/g A +/− C G C G A A
S057 Lipizzaner G/g A +/− C G C G A A
899 Arabian G/g A +/− C A/G T/C A/G A or G/A A/T
222 Arabian G/g A +/− C A/G T/C G/A
5726 Connemara G/g A +/− C A/G T/C G/A
6591 Connemara G/g A +/− C A/G T/C G/A
D081 Lipizzaner G/g A +/− C A/G T/C G/A
D076 Lipizzaner G/g A/G +/− C A/G T/C G/A
213 Arabian G/g A +/− C/T A/G T/C G/A
D091 Lipizzaner G/g A +/− C/T A/G T/C G/A
D007 Lipizzaner G/g A/G +/− C/T A/G T/C G/A
D010 Lipizzaner G/g A/G +/− C/T* A/G T/C G/A
678 Arabian G/g A +/− C/T G T/C G/A
D004 Lipizzaner G/g A +/− C/T G T/C G/A
452 Thoroughbred G/g A +/− C G T/C G/A
3156 Lipizzaner G/g A +/− C G T/C G/A
6577 Welsh G/g A +/− C G T/C G/A
6611 Shetland G/g A +/− C G T/C G/A
SP1 Connemara:Sp G/g A +/− C G T/C G/A
SP2 Connemara:Sp G/g A +/− C G T/C G/A
SP3 Connemara:Sp G/g A +/− C G T/C G/A
SP4 Connemara:Sp G/g - +/− C G T/C G/A
D192 Lipizzaner G/g A/G +/− C G T/C G/A
1271 Icelandic G/g A +/− C G T A G A/T
P023 Lipizzaner G/g A/T A/G +/− C A/G T/C G/A
S065 Lipizzaner G/g A/T A/G +/− C - T/C G/A
P038 Lipizzaner G/g A/T A/G +/− C A/G T/C G/A
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failed and those two SNPs were therefore genotyped in
key individuals using Sanger sequencing (Table 3).
The non-reference alleles at SNP1 and SNP3 were
only found in a fraction of Grey individuals (Table 3),
which means that these SNPs must have occurred subse-
quent to the Grey mutation. SNP1 is located in a verte-
brate conserved element of approximately 20 bp (UCSC
Genome Browser; Human Feb. 2009 GRCh37/hg19 As-
sembly), with a high regulatory potential score (UCSC
Genome Browser; Human Mar. 2006 NCBI36/hg18 As-
sembly), while SNP3 is not. Possibly, due to its location
in a conserved element, SNP1 could be functionally im-
portant, but this was not further investigated in the
present study. For SNP1, a fourth, distinct separate
genotype cluster was detected in the TaqMan analysis.
By sequencing the amplicon for the individuals in this
cluster, a SNP in the TaqMan probe site was detected,
resulting in a lower G-allele signal in the assay, thereby
creating a fourth cluster. Since the G nucleotide is asso-
ciated with Grey, this analysis revealed a third confirmed
SNP at position 6,553,858 bp, (SNP0 in Table 3) which
must have occurred on the Grey haplotype subsequent
to the Grey mutation event.
SNP4 and SNP6 showed a nearly perfect association
with the Grey genotype, but with the exception of two
non-Grey and four heterozygous Grey individuals
(Table 3). For these individuals the SNP4, SNP6 and the
Grey duplication statuses were confirmed by Sanger se-
quencing or long-range PCR, respectively. Based on the
results, these two SNPs are located just outside the
haplotype block showing complete LD with the Grey
mutation. Similarly, Sanger sequencing of SNP5 and
SNP7, located in the vicinity of SNP6, showed that nei-
ther one was in complete LD with Grey.
In conclusion, this effort to resequence the entire
352 kb region associated with Grey and then further
Table 3 TaqMan genotyping of SNPs in the Grey region (Continued)
L034 Lipizzaner G/g A/T A/G +/− C A/G - G/A
P076 Lipizzaner G/g A/T A/G +/− C A/G T/C G/A
L040 Lipizzaner G/g A/T A/G +/− C/T A/G T/C G/A
L049 Lipizzaner G/g A/T A/G +/− C/T A/G T/C G/A
D007 Lipizzaner G/g A/T A/G +/− C/T A/G T/C G/A
230 Arabian G/G A +/+ C A T G
L010 Lipizzaner G/G A +/+ C A T G
D080 Lipizzaner G/G A/G +/+ C A T G
D006 Lipizzaner G/G G +/+ C A T G
399 Arabian G/G A +/+ C/T A T G
857 Arabian G/G A +/+ C/T* A T G
L004 Lipizzaner G/G A +/+ C/T A T G
D089 Lipizzaner G/G A/G +/+ C/T A T G
D098 Lipizzaner G/G G +/+ C/T A T G
6210 Lipizzaner G/G A +/+ C A/G T G
D009 Lipizzaner G/G A/G +/+ C A/G T G
D079 Lipizzaner G/G A +/+ C/T A/G T G
P086 Lipizzaner G/G A +/+ C/T* A/G T G
D003 Lipizzaner G/G A/G +/+ C/T A/G T G
L053 Lipizzaner G/G A/G +/+ C/T* A/G T G
L024 Lipizzaner G/G A +/+ C G T G
6580 Welsh G/G A +/+ C/T G T G
D102 Lipizzaner G/G A +/+ C/T G T G
L090 Lipizzaner G/G A +/+ C/T* G T G
Results from TaqMan genotyping of selected SNPs located in the Grey region in 357 non-Grey and Grey horses from 8 different breeds, including the late-greying
Connemara horses (Connemara:Sp) and Arabian horses (Arabian: Anc) carrying a non-Grey haplotype that is ancestral or closely related to the Grey haplotype. The
table shows representative genotypes selected from all breeds. For SNP2, individuals with a strong signal for the variant T allele (C/T ratio equal 1) are marked
with an asterisk. SNP0 SNP5 and SNP7 were genotyped by Sanger sequencing only in key individuals. SNP0 is at nucleotide position 6,553,858 in STX17.
1SNP1 is at nucleotide position 6,553,868 in STX17; Dup is the 4.6 kb duplication in STX17 causing Grey; SNP2 is at nucleotide position 6,587,140 in STX17; SNP3 is
at nucleotide position 6,640,661 in TXNDC4; SNP4 is at nucleotide position 6,775,832 in INVS; SNP5 is at nucleotide position 6,778,924 in INVS; SNP6 is at
nucleotide position 6,782,059 in INVS; SNP7 is at nucleotide position 6,790,986 in INVS.
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genotyping a set of candidate SNPs with strong associa-
tions, has provided extensive support for our previous
conclusion that the 4.6 kb duplication in STX17 is the
causative mutation for Grey. We did not identify any
other sequence polymorphism uniquely associated with
Grey across breeds, where the genotype distribution per-
fectly matched the Grey phenotype.
SNP2 is duplicated in the horse genome
Surprisingly, SNP2 did not show any significant linkage
disequilibrium to Grey at all, in contrast to all other pre-
viously analyzed sequence polymorphisms located in the
Grey critical interval [2]. Thus, this SNP cannot be
involved in determining the Grey phenotype. In TaqMan
analysis of this SNP, situated in the 3'UTR of STX17,
two clearly distinct genotype clusters of individuals that
appeared as heterozygous C/T were detected, one cluster
with a slightly higher T signal. This additional cluster
contained non-Grey, heterozygous Grey and homozy-
gous Grey individuals, a finding which shows that this
polymorphism shows no LD with Grey (Table 3). Sanger
sequencing confirmed a heterozygous SNP genotype,
and also confirmed the higher signal from the T-allele in
some individuals (data not shown). Furthermore, no
individuals homozygous for the T-allele were identified
in the TaqMan assay, indicating that SNP2 could not be
in Hardy-Weinberg equilibrium; the expected number of
horses homozygous for the T-allele in this material was
eight. We hypothesized that this anomalous result could
be due to this SNP representing a second transposed
copy present somewhere else in the genome. This was
confirmed by a PCR-based approach used in order to
determine the size of the transposed fragment. We
investigated this by amplifying fragments 1 to 5 kb flank-
ing the SNP, followed by SNP genotyping by Sanger se-
quencing. Since the T allele was only detected when the
flanking primer was located not more than 1 kb up-
stream or downstream of the polymorphic nucleotide,
we could estimate the size of the transposed fragment to
approximately 2 kb and it does not overlap the Grey du-
plication. Three additional nucleotide positions differing
between the STX17 3'UTR sequence and the transposed
fragment were identified (data not shown). However, we
were not able to reach out into unique sequences flank-
ing the transposed fragment by chromosome walking,
which would have allowed us to determine the exact
genomic position of the second copy of this sequence.
An alternative way would be to map the location of this
SNP with classical linkage analysis.
In conclusion, our interpretation of this anomalous
SNP is that it represents a transposed copy in which the
nucleotide corresponding to the C nucleotide at position
6,587,140 bp in STX17 3'UTR has been replaced with a
T. Animals scored as CC in this assay either lack the
transposed copy or carry a transposed copy with a C at
this position. The two clusters with different C:T ratios
represent horses carrying one or two copies of the trans-
posed sequence with the T nucleotide. The fact that this
sequence is located elsewhere in the genome explains
the complete lack of linkage disequilibrium with the
Grey allele (Table 3).
Discussion
Tandem duplications are notoriously unstable and often
show copy number variation [18]. In this study we have
explored the possibility that the 4.6 kb duplication caus-
ing Greying with age in horses exhibits copy number
variation in constitutional and/or tumour DNA. We
show that there is a difference in copy number of the
Grey duplication between constitutional DNA and
tumour DNA, with the highest copy number found in
tumours classified as aggressive or derived from horses
euthanized possibly due to numerous internal tumours.
When screening copy number expansion in constitu-
tional DNA, we found only one horse out of about 90
with an estimated copy number of 5 or higher, whereas
the corresponding figure for tumour DNA was 5 out of
8 (P = 5x10-6; Fisher’s exact test). The elevated copy
number in tumour DNA compared with constitutional
DNA constitutes the first set of proof that the duplica-
tion in STX17 not only predisposes to melanoma devel-
opment, but that copy number expansion of the
duplicated sequence may be a driving force in melanoma
development. The three horses showing a higher copy
number in melanoma tissue than expected from their
zygosity for Grey, were all euthanized possibly due to
what might be internal melanoma metastases (ID1, ID2,
ID3; Table 1, Figure 2B). mRNA from the tumour sam-
ples ID1 and ID2 were used for expression analysis in
our previous study [19] and both samples had upregu-
lated expression of STX17 and NR4A3 consistent with
our interpretation that the copy number expansion
detected in the present study may be relevant for
tumour development. The melanoma cell lines showing
a higher copy number than expected from the Grey
genotype, Ho-Mel-A1 (Seltenhammer et al., in prepar-
ation) and M14 [20], have both been characterized as
malignant, with M14 showing a high expression of the
proliferating cell nuclear antigen PCNA [20], previously
correlated with aggressive behaviour of human cutane-
ous malignant melanoma [19].
The present study has provided strong genetic support
for our previous conclusion that the 4.6 kb duplication
in intron 6 of STX17 causes Greying with age [19].
Firstly, the copy number expansion seen in tumours sug-
gests that it may promote tumour progression. Secondly,
our careful resequencing strategy of the 352 kb region
showing complete association with Grey failed to identify
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any other sequence polymorphisms than the duplication
that showed a perfect concordance with the phenotype.
Furthermore, in a recent study we provided strong
support for the functional significance of the duplica-
tion [21]. We demonstrate using transfection experi-
ments and transgenic zebrafish that the duplicated
sequence contains a melanocyte-specific regulatory elem-
ent that is MITF (microphtalmia-associated transcrip-
tion factor)-dependent. The data showed that the
duplication transforms a weak enhancer element to a
strong melanocyte-specific enhancer [21]. Thus, it is
possible that further amplifications of the duplicated
sequence, as observed in tumour samples in the present
study, promote tumour development.
The great majority of sequence polymorphisms
present in domestic animals predate domestication [22].
Thus, most SNP alleles associated with Grey can be
expected to be shared with non-Grey haplotypes as
demonstrated in this study. However, we identified three
nucleotide polymorphisms that were only found in a
subset of Grey horses despite the fact that they were
located within the region where all sequence polymorph-
isms show complete LD with Grey. Thus, these sequence
polymorphisms must have arisen subsequent to the Grey
mutation. This result is fully consistent with the pre-
sumed long history of the Grey duplication, with an esti-
mated age older than 2,000 years [2]. This assumption is
based on the fact that all tested Grey horses representing
breeds from all over the world share the same mutation
that must have occurred early during horse domestica-
tion to become as widespread as it is. Furthermore, there
is abundant written records 2,000 years old and older in-
dicating the occurrence of white horses.
There is a considerable variation in how fast greying
proceeds in Grey horses, and in our previous study we
demonstrated that Grey homozygotes grey faster than
Grey heterozygotes [2]. In this study, we have shown
that several late greying Connemara horses have a copy
number of three for the STX17 duplication, as expected
for a heterozygous Grey horse (Additional file 2). Add-
itionally, for the investigated SNPs, they proved to have
the same haplotype as Grey horses from other breeds.
This shows that the late greying phenotype in these
horses is caused by the same allele as in other Grey
horses, whereas there must be other modifying genetic
variation in the vicinity of the Grey mutation or else-
where in the genome.
A surprising finding in this study was that one of the
SNPs corresponding to the nucleotide position
6,587,140 bp on horse chromosome 25, i.e. in the region
showing complete LD with Grey, did not show any signs
of LD with Grey. We showed that this anomaly occurs
because this segment is duplicated in the horse genome
and that the polymorphism is derived from the other
genomic location explaining the lack of LD with Grey.
The location of this second copy was not revealed in the
present study but it should be straightforward to search
for its location using next-generation sequence data in
particular since the transposed fragment is only about
2 kb in size. It is possible that the presence of transposed
copies of duplicated sequences is an explanation for
other similar cases of one or more non-associated SNPs
within an ocean of strongly associated SNPs.
Conclusions
In this paper we show that a 4.6 kb duplication in Syn-
taxin 17, associated with the Grey phenotype in horses,
does not only predispose to melanoma development, as
previously shown, but that a copy number expansion of
the duplication may be a driving force for melanoma de-
velopment. The extensive genetic analysis, including
resequencing of the 352 kb Grey haplotype, confirms
that the 4.6 kb duplication is the causative mutation for
this phenotype as no other polymorphism showed a
complete concordance with the phenotype. The elucida-
tion of the mechanistic features of the duplication will
be of considerable interest for the characterization of
these horse melanomas as well as for the field of human
melanoma research.
Methods
Duplication copy number variation analysis by qPCR
(TaqMan)
Constitutional DNA was prepared from blood or skin,
and tumour DNA was prepared from melanoma cell cul-
tures or melanomas (Table 1) using the DNeasy Blood &
Tissue kit (Qiagen, Valencia, CA, USA) according to
manufacturer’s protocol. Since the high melanin content
in the melanomas can interfere with subsequent applica-
tions, the tumour DNA was purified with Chroma Spin
TE-1000 columns (Clontech Laboratories Inc., Mountain
View, CA, USA) as described in the standard protocol.
DNA from the late greying Connemara horses was pre-
pared either from hair by incubating 5–7 hair roots for
60 min at 56°C, in a total volume of 100 μl 5% chelex,
containing 140 μg proteinase K, or from 100–200 μl of
blood using the E.Z.N.A.W SQ Blood DNA Kit (OMEGA
Bio-Tech Inc., Norcross, GA, USA).
Assays for testing the potential copy number variation
of the STX17 duplication and the reference gene assays
were designed in PrimerExpress (Applied Biosystems,
Foster City, CA, USA). Probes were designed inside and
outside the duplicated sequence, and also spanning the
5' flanking sequence and the 5'end of the duplicated se-
quence and over the duplication breakpoint (Additional
file 3). For each region of interest, four replicate CT
values were obtained per sample with FAM™ labelled
probes for the specific regions and VICW labelled probes
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in the reference gene assays. Two reference gene assays,
RNaseP and TERT, were tested according to the recom-
mendations by Applied Biosystems, but only the RNaseP
assay was used in the analysis since TERT showed signs
of amplification or deletion in several samples, as could
be expected in cancer cells [23]. TaqMan Copy Number
Assays were performed according to the manufacturer's
instructions (Applied Biosystems) and using an
ABI7900HT instrument. The results were analyzed in
CopyCaller™ Software v1.0 (Applied Biosystems). The
samples used in the assays consisted of blood DNA from
one non-Grey calibrator sample, 32 heterozygous and 62
homozygous Lipizzaner horses, hair DNA from three
late greying Connemara horses SP1, SP2 and SP3 (Add-
itional file 2); tumour DNA from four equine melanoma
cell lines M1, M14 [20], Ho-Mel-A1 and HO-Mel-L1
(Seltenhammer et al., in preparation), tumour DNA from
one heterozygous Grey individual: ID1, and paired con-
stitutional and tumour DNA from one homozygous
Grey individual: ID2, and two heterozygous Grey indivi-
duals: ID3 and ID4.
Targeted resequencing
Two individuals were expressly chosen for massively
parallel resequencing of the region surrounding the Grey
mutation locus. One was a Lipizzaner horse (ID: L147)
homozygous for Grey (Grey sample). The other was a
non-Grey chestnut Arabian horse (ID: 800), with the
closely related haplotype on which the Grey mutation
occurred (i.e. “ancestral” non-Grey sample). In addition,
five other non-Grey horses were included in the experi-
ment: an Appaloosa, an Icelandic, a Knabstrupper, a
Noriker and a Quarter Horse. The samples were pre-
pared for sequencing as follows. Genomic DNA was
fragmented and purified on QIAquick columns (Qiagen).
Fragment ends were blunted and 5' phosphorylated, and
a 3' overhang of a single adenosine was added. Illumina
adapters (Illumina, San Diego, CA, USA) were ligated to
the DNA fragments, which were subsequently hybri-
dized to NimbleGen Sequence Capture Arrays (Roche
NimbleGen, Madison, WI, USA), following manufac-
turer's recommendations. The arrays were designed to
target the 352 kb region on horse chromosome 25, har-
bouring the haplotype previously associated to Grey. Fol-
lowing enrichment for target fragments on the arrays,
Illumina adapter ligated fragments were amplified with
adapter specific primers using a high-fidelity polymerase
(Phusion, Finnzymes, Espoo, Finland) and purified on
QIAquick columns (Qiagen). The enrichment-factor for
each sample was assessed by quantitative PCR compari-
son to the same samples prior to hybridization. The
enriched samples were then sequenced with Illumina
Genome Analyzer (Illumina), obtaining single-end 35 bp
reads. Mapping of the reads and SNP calling were
performed with the standard parameters of the MAQ
program, version 0.6.6 [24].
Genotyping
The inferred genotypes for 10 selected SNPs were con-
firmed by PCR followed by Sanger sequencing of three
individuals; Twilight, the thoroughbred mare that the
genome sequence is derived from is heterozygous for
Grey [17], an homozygous Grey horse (ID: L032) and
the individual with a non-Grey haplotype closely related
to Grey (ID: 800). Subsequently, TaqMan SNP Genotyp-
ing Assays were designed for five SNPs being either
polymorphic in the Grey individual or not showing link-
age disequilibrium with Grey (Figure 3 and Additional
file 3). SNPs polymorphic among non-Grey individuals
were not considered for further analysis, since we aimed
at identifying other mutations associated with the Grey
phenotype. In total, 357 Grey and non-Grey horses from
8 different breeds were genotyped for the selected SNPs
in order to investigate if any of these SNPs could be
associated with the Grey phenotype. Four Connemara
horses with the late greying phenotype were included
among these 357 horses to investigate possible add-
itional mutations in the Grey haplotype. Samples were
genotyped on an ABI7900HT instrument using the Taq-
Man allelic discrimination assay according to the manu-
facturer's instructions (Applied Biosystems). Each SNP
was genotyped twice for every individual. The SNPs in
repetitive regions were amplified by PCR for informative
individuals and genotyped by Sanger sequencing (Add-
itional file 3).
The Grey mutation was genotyped with long range
PCR as previously described [2]. Since this method
requires amplification of fragments >4 kb, the DNA iso-
lated from hair samples or old blood samples of late
greying Connemara horses could not be used. Therefore,
their Grey genotypes were deduced from the TaqMan
Copy Number Assay.
Identification of a transposed fragment originating from
STX17 3'UTR
To identify the approximate size of a duplicated frag-
ment corresponding to the sequence in the STX17
3'UTR that could explain the results from the TaqMan
SNP screen, PCR products from two individuals geno-
typed as homozygous C/C, two individuals genotyped as
C/T but with a C/T-ratio of 3:1 and two individuals gen-
otyped as C/T with a C/T-ratio of 2:2 were amplified 5,
4, 3, 2 and 1 kb upstream and downstream of SNP2
(Additional file 3) using the Expand Long Template PCR
system Mix 1 (Roche Diagnostics GmbH, Mannheim,
Germany), in 25 μl reactions using 125 ng of genomic
DNA. The PCR products were treated with ExoI and calf
intestine alkaline phosphatase (CIAP) in ExoI buffer (all
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from Fermentas, St. Leon-Rot, Germany) at 85°C for
60 min to remove free nucleotides and excess primers
prior to sequencing. The SNP was then genotyped by se-
quencing with primers flanking the polymorphism (Add-
itional file 3). Sequences were analyzed and screened for
mutations with Codon Code Aligner (CodonCode Cor-
poration, Dedham, MA, USA).
Additional files
Additional file 1: Lack of copy number variation outside and over
the 5’breakpoint of the STX17 duplication in constitutional DNA
from Grey horses. 94 Grey Lipizzaner horses and one calibrator sample
with a known copy number of 2 were included in the analysis. OUT =
outside the duplicated sequence and BP n = the border between the
5’flanking sequence and the 5’end of the duplicated sequence. Error bars
represent the copy number range from the CopyCaller™ Software
analysis of quadruplicates in each assay.
Additional file 2: The late greying Connemara horses are
heterozygous for the STX17 duplication. Copy number assay for the
STX17 duplication from tests with four different probes using
constitutional DNA from the late greying Connemara horses SP1, SP2,
SP3. The sample denoted ‘Calibr’ is a g/g individual with a known copy
number of 2, used as a calibrator in the IN, OUT and BP n analyses.
Constitutional DNA from one G/g and one G/G horse was tested in the
assay and the results are shown as a reference for the copy number
expected from each genotype. The G/G reference sample was used as a
calibrator in the BP d analysis. IN = inside the duplicated sequence,
OUT = outside the duplicated sequence, BP n = the border between the
5’flanking sequence and the 5’end of the duplicated sequence and
BP d = over the duplication breakpoint. Error bars represent the copy
number range from the CopyCaller™ Software analysis of quadruplicates
in each assay.
Additional file 3: Primer sequences used for characterization of the
region harbouring the Grey mutation in horses.
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